30 closest matches · ranked by relevance
Neutropenia · Infection
Primary: Percentage of Participants Who Are Alive at 42 Days After Treatment and Have Had Microbial Response — 42.9; 41.7 percentage of participants — p=0.73
Acute Myeloid Leukemia · Neutropenia · Bacteremia
Primary: Occurrence of Post-chemotherapy Bacteremia — 22; 81 Participants
Febrile Neutropenia
Primary: Composite Primary Endpoint: Number of Participants With an Overall Favorable Response to Echinocandin Therapy for Empiric Antifungal Therapy for Persistent Febrile…
Breast Cancer · Non-Small Cell Lung Cancer · Ovarian Cancer
Primary: Percentage of Participants With Febrile Neutropenia (FN) — 8; 8; 15; 9 percentage of participants
Pediatric Acute Myeloid Leukemia
Primary: Compare Differences in HRQOL Scores Between Outpatient Versus Inpatient Management — 70.1; 68.7 score on a scale
Fever · Sweating · Hot Flashes
Primary: Number of Participants Who Became Afebrile Within 72 Hours of Starting Daptomycin. — 16 participants
Mycoses
Primary: Incidences of Invasive Fungal Diseases (IFD) — 11.76; 10.14; 23.19 percentage of partipants
Herpes Simplex
Primary: Number of Participants Experiencing Incidence of Nephrotoxicity, Defined as a Serum Creatinine ≥ 2 Times the Patient's Baseline — 2; 3 participants
Possible Fungal Infection
Primary: Number of Participants With Proven or Probable Invasive Fungal Infections (IFI): Complete Case Analysis — 6; 9 participants — p=0.258
Acute Myeloid Leukemia · Myelodysplastic Syndrome · Neutropenia
Primary: Number of Participants With Proven or Probable Invasive Fungal Infections (IFIs) — 4 Participants
Febrile Neutropenia
Primary: Mean (SD) Doripenem Pharmacokinetic Volume of Distribution Parameter in Febrile Neutropenic Patients — 36.7; 49.9; 43.9 Liters
Prophylaxis Of Invasive Fungal Infections
Primary: Occurrence of Proven or Probable Invasive Fungal Infection (IFI): Start of Prophylaxis Until 12-month Follow-up Visit — 3 participants
Invasive Fungal Infections
Primary: The Rate of Invasive Fungal Infections — 77; 27 participants — p=0.007
Pulmonary Infiltrate New
Primary: Number of Patients With Positive Culture or Molecular Results After Brochoscopy — 40 participants
PICC · Central Venous Catheter · Central Line
Primary: Participants With Complications With Central Access Including Insertion — 14; 10 Participants — p=0.271
Acute Myelogenous Leukemia · Myelodysplastic Syndrome
Primary: Time to Failure — 16; 13 Days
Hematopoietic and Lymphoid Cell Neoplasm · Malignant Solid Neoplasm
Primary: Clinical Outcome in the MITT Analysis Set at EOIV. — 44; 37; 5; 12 Participants
Fusariosis · Onychomycosis
Primary: Proportion of Patients Who Develop Invasive Fusariosis Until Neutrophil Recovery — 6; 8 Participants
Hodgkin Disease · Non-Hodgkin Lymphoma · Multiple Myeloma
Primary: Incidence of Clinically Significant Bacteremia — 3; 9 participants
Febrile Neutropenia · Cancer · Breast Cancer
Primary: Chemotherapy Toxicity (%FN Risk) — 154; 650; 640; 3 participants
Mycoses · Leukemia
Primary: Percentage of Participants With Non-Candida Invasive Fungal Infections at a Single Institution — 32.3 Percentage of participants
Other Infectious Diseases
Primary: Number of Participants With Favorable Clinical Response at End of Inpatient Intravenous Therapy (EOIV) — 41; 36 Participants
Allogeneic Stem Cell Transplantation · Refractory Autoimmune Cytopenia(s)
Primary: Number of Participants With Response — 3; 2; 1 participants
Febrile Neutropenia
Primary: Percentage of Participants Receiving Antibacterial Agents Preferred by the Turkish Centers Monitoring Febrile Neutropenia (FEN) in Their Therapeutical Approach…
Graft-Versus-Host Disease
Primary: The Percentage of Participants Experiencing Acute GVHD After Allogeneic Hematopoietic Stem Cell Transplantation (HSCT) — 45; 18 percentage of participants
Chemotherapy-induced Febrile Neutropenia
Primary: Percentage of Participants With Febrile Neutropenia — 3.3; 1.9; 0.4; 0.5 percentage of participants
Acute Myeloid Leukemia · Adult Acute Monoblastic Leukemia · Adult Acute Monocytic Leukemia
Primary: Percentage of Participants With Proven or Probable Invasive Fungal Infections (IFI) — 3.1; 7.2 Percentage of participants
Febrile Neutropenia · Stage 0 Breast Cancer · Stage 0 Colorectal Cancer
Primary: Percentage of Participants With CSF Prescribed as Primary Prophylaxis — 8.3; 5.5; 7.2; 5.3 percentage of participants — p=0.21
Non-Interventional Study
Primary: Percentage of Participants With Any Significant Comorbidities — 42.7 percentage of participants
Invasive Candidiasis
Primary: Proven and Probable Invasive Candidiasis Based on Modified Mycoses Study Group/European Organization for Research and Treatment of Cancer (MSG/EORTC) Criteria. — 9.8…